XTalks

DECEMBER 4, 2024

Jotrol overcomes these barriers using patented micellar technology, enhancing bioavailability and enabling therapeutically effective doses. CAMP4’s RNA-based therapies focus on genetic diseases like urea cycle disorders, while Rapport’s small molecules aim to address epilepsy, pain and bipolar disorder.

Bioavailability 111

Bioavailability Genetic Disease Marketing RNA 111

The Pharma Data

JANUARY 5, 2021

Durham, North Carolina-based Ribometrix announced a strategic collaboration deal with Genentech , a Roche company, to identify and advance novel RNA-targeted small molecule therapeutics. Targeting RNA is believed to be a way to develop therapeutics for so-called undruggable proteins. The first identifies the 3D RNA motifs.

RNA 52

RNA Protein Bioavailability DNA 52

XTalks

JUNE 14, 2023

Furthermore, the bioavailability of the active pharmaceutical ingredient (API) into the cornea is up to four times stronger with EyeSol technology. In addition, Sylentis, a biotech company specializing in ophthalmic drugs and RNA interference (RNAi) technology, initiated a Phase III study in 2021.

Gene Silencing 97

Gene Silencing Drug Delivery FDA Approval RNA 97

Roots Analysis

MAY 21, 2024

In fact, it has been observed that around 40% of the pharmaceutical drugs approved by regulatory organizations exhibit poor bioavailability / solubility. Further, every year, poor bioavailability is one of the main causes of drug failure in obtaining approval authorization.

Drug Delivery 40

Drug Delivery Drugs Gene Therapy Bioavailability 40

Delveinsight

JANUARY 7, 2021

Ribometrix will apply its proprietary discovery platform to recognize and optimize small molecule compounds, which modulate RNA function by aiming three-dimensional (3D) RNA structures. Ribometrix has presented that many RNAs implicated in disease comprise structural pockets amenable to targeting with small molecules.

RNA 52

RNA Clinical Trials Clinical Trials Bioavailability 52

XTalks

AUGUST 30, 2022

A major obstacle for CNS drug developers is the inability to target therapies to the CNS broadly (for instance, a therapy that is orally bioavailable as a pill and has difficulty crossing the blood-brain barrier) and certain CNS regions more specifically. The patients are waiting! Modern-Day Applications of Direct CNS Administration.

Trials 83

Trials Drug Delivery Drugs Gene 83

Roots Analysis

JANUARY 28, 2024

Some of the areas she has worked on include protein design and engineering, metabolomics services, bioavailability enhancement technologies and services, plasmid DNA manufacturing, NAMPT inhibitors, and big data analytics in healthcare domain.

Big Data 40

Big Data Medicine Marketing Clinical Trials 40